|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Zantac
|
|
gptkbp:activities
|
H2 receptor antagonist
|
|
gptkbp:approves
|
gptkb:1981
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Zantac
|
|
gptkbp:clinical_trial
|
studies on efficacy
studies on safety
studies on dosage
studies on drug interactions
studies on long-term use
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to ranitidine
|
|
gptkbp:discontinued
|
due to safety concerns
|
|
gptkbp:dosage_form
|
75 mg
150 mg
300 mg
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:tablet
suspension
injection solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ranitidine
|
|
gptkbp:ingredients
|
C13 H12 N4 O3 S
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:procainamide
gptkb:warfarin
|
|
gptkbp:is_available_on
|
gptkb:product
gptkb:tablet
injection
|
|
gptkbp:is_used_for
|
treating gastroesophageal reflux disease (GERD)
treating stomach ulcers
preventing heartburn
|
|
gptkbp:manager
|
oral
intravenous
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:related_to
|
gptkb:nizatidine
gptkb:cimetidine
gptkb:famotidine
|
|
gptkbp:replaced_by
|
gptkb:2019
|
|
gptkbp:side_effect
|
gptkb:historical_event
dizziness
headache
nausea
confusion
diarrhea
liver damage
constipation
kidney issues
cardiac arrhythmias
|
|
gptkbp:type_of
|
66357-35-5
|
|
gptkbp:wildlife
|
elderly patients
breastfeeding
renal impairment
pregnancy category B
hepatic impairment
|